Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent ki...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5797045/
https://ncbi.nlm.nih.gov/pubmed/29435174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23749
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars